AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

[News]

Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie’s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

More... (http://www.news-medical.net/news/20141104/AbbVie-and-Myriad-Genetics-expand-Tumor-BRACAnalysis-CDx-collaboration.aspx)